Study of the role of iron in the anticryptococcal activity of human serum and fluconazole

Mycopathologia

Volumn 133, Issue 2, 1996, Pages 71-77

  Grover, Devina D ^b   Brummer, Elmer ^b   Stevens, David A ^a  

^a SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^b NONE

Author keywords

cryptococcus; fluconazole; iron; serum

Indexed keywords

FILOBASIDIELLA NEOFORMANS;

EID: 0029758484     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00439116     Document Type: Article

References (8)

1. Anonymous. Cryptococcosis and AIDS. Lancet 1988; 1: 1434-1436.
2. Howard DH. Some factors which affect the initiation of growth of Cryptococcus neoformans. J Bacteriol 1961; 82: 430-435.
3. Baum GL, Artis D. Characterization of the growth inhibition factor for Cryptococcus neoformans in human serum. Am J Med 1963; 87: 53-57.
4. Szilagyi G, Reiss F, Smith JC. The anticryptococcal factor of blood serum. J Invest Dermatol 1966; 46: 306-308.
5. Igel JH, Bolande RP. Humoral defense mechanism in cryptococcosis: Substances in normal human serum, saliva, and cerebrospinal fluid affecting the growth of Cryptococcus neoformans. J Inf Dis 1966; 116: 75-83.
6. Esterly NB, Brammer SR, Crounse RG. The relationship of transferrin and iron to serum inhibition of Candida albicans. J Invest Dermatol 1967; 49: 437-442.
7. Bennett JE, Grant S (eds). Fluconazole: an Overview. Langhorne, Pennsylvania: ADIS Press International, 1990: 82 pp.
8. Nassar F, Brummer E, Stevens DA. Different components in human serum inhibit multiplication of Cryptococcus neoformans and enhance fluconazole activity. Antimcrob Agents Chemother 1995; 39: 2490-2493.